article
Drug Target Review’s highlights from ELRIG Drug Discovery 2022
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
List view / Grid view
Drug Development
news
Researchers have developed a drug that can break through the mucus barrier
A capsule that tunnels through mucus in the gastrointestinal tract could be used to orally administer large protein drugs such as insulin.
article
Right model, right complexity: using in vitro human disease cell models in drug discovery
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
article
Synthetic biology is ready for the therapeutic limelight
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
article
Advancing novel biotherapeutics based on synthetic biology
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
news
Study reveals how tau impairs communication between neurons in Alzheimer’s
A new study has shown how tau weakens transmission across synapses in the brains of mice, providing insight into Alzheimer's.
news
Screening reveals modulators of macrophage training and SARS CoV-2 infection
Researchers screened biologically active small molecules, finding several compounds with the ability to induce training effects on macrophages.
article
Next-generation CRISPR technologies for treating human diseases
Genome editing technologies could accelerate the translation of genetic advances into new therapeutics. Here, Dr Pushpanathan Muthuirulan, Research Associate at Harvard University, explores the potential of CRISPR to treat and cure genetic conditions.
article
Drug Target Review Assays ebook 2022
Included in this ebook are pieces on how an assay for the detection of sepsis was developed and a new high-throughput assay that could reveal new drugs to fight COVID-19.
article
Drug Target Review – Issue 3 2022
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
news
Luminescent sensor could enable high-throughput screening in presence of fluorescence
A bioluminescence resonance energy transfer sensor has been developed to report changes in intracellular Ca2+ concentrations during screening.
news
Researchers discover compound that could treat Chagas disease
Using screening techniques, researchers have identified the compound called AN15368 which works as an antiparasitic against Chagas disease.
podcasts
Episode 12 – ELISA assays with Dr Ana Miletic and Anna Dey, Kyowa Kirin & Dr Cathy Olsen, Molecular Devices
In this episode, experts discuss how they use ELISA assays in their research as well as the specific benefits of this kind of immunoassay.
news
Molecular Devices and HeartBeat.bio announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery
Molecular Devices has announced a collaboration with HeartBeat.bio to develop cardiac organoids for use in drug discovery.
webinar
Decoding cancer and inflammation: identifying selective inhibitors of SH2 domains
31 August 2022 | By Eurofins Discovery
Watch our on-demand webinar where our expert speaker will explore the possibilities for designing selective small molecules targeting the SH2 domains of STAT proteins plus more.
